Windlas Biotech concludes SAHPRA audit with an all-clear sign

It will enable the company to branch out to new geographies and strengthen its presence in South Africa

Windlas Biotech, a leading player in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India, has concluded SAHPRA (South African Health Products Regulatory Authority) inspection audit report for the Plant-IV situated at Dehradun with zero critical observations / deficiencies, zero major deficiencies and some minor deficiencies. The company had undergone the inspection audit from 20th to 29th September 2021.

Commenting on this Hitesh Windlass, Managing Director - Windlas Biotech said, "We are very happy to receive zero critical observations and deficiencies. The successful completion of the audit will enable us to open up new geography and strengthen our presence in South Africa.